Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or... March 3, 2025 Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... February 27, 2020 Working Mom with Stage II Breast Cancer Receives Custom Wig Made... July 30, 2020 FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma November 13, 2024 Load more HOT NEWS Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... Dame Deborah James: why do deeply personal stories resonate with us... Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS...
